Glaukos Raises 2026 Revenue Outlook to $600–620M After Q4 Revenue Beat
Glaukos reported Q4 revenues of $143.1 million, up 36% year over year, beating estimates by 6% but recording an adjusted loss of $0.28 per share versus a $0.22 estimate. The company raised its 2026 revenue guidance to $600–620 million and highlighted adoption drivers including iDose TR and upcoming Epioxa launch.
1. Fourth-Quarter Financial Results
Glaukos generated Q4 2025 revenues of $143.1 million, a 36% year-over-year increase that exceeded consensus by 6%. The company reported an adjusted loss of $0.28 per share, improved from a $0.40 loss a year ago but missing the $0.22 estimate.
2. 2026 Guidance and Outlook
For 2026, Glaukos projects net sales of $600 million to $620 million, above the $610.6 million consensus forecast, and anticipates a $0.33 per share loss reflecting a 60.9% improvement. Cash and equivalents rose to $282.6 million at year-end, supporting investment in growth initiatives.
3. Product Developments and Pipeline
Management highlighted rapid adoption of iDose TR following FDA approval for unlimited re-administration and expects Epioxa, the first non-epithelium removal topical therapy, to launch later this quarter. The company is building a site-of-care network covering 50% of the U.S. population and engaging payers ahead of a permanent J-code in July 2026.